Logo

High Response Rate With First Targeted Drug for Bladder Cancer

ARTICLES

High Response Rate With First Targeted Drug for Bladder Cancer


MEDSCAPE
PUBLISHED: 25 JULY 2019


erdafitinib showed an overall response rate (ORR) of 32.3%.Now the full results of the phase 2 clinical trial on which that approval was based have been published in the New England Journal of Medicine.

explore_now-footer.png

Published

July 25, 2019

Categories

Oncology
CP-202103